1. Home
  2. BHAT vs LIXT Comparison

BHAT vs LIXT Comparison

Compare BHAT & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BHAT

Blue Hat Interactive Entertainment Technology

HOLD

Current Price

$0.68

Market Cap

27.7M

ML Signal

HOLD

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$3.07

Market Cap

25.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BHAT
LIXT
Founded
2010
2005
Country
China
United States
Employees
N/A
4
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.7M
25.3M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
BHAT
LIXT
Price
$0.68
$3.07
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
70.5M
27.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.03
$0.64
52 Week High
$3.94
$6.09

Technical Indicators

Market Signals
Indicator
BHAT
LIXT
Relative Strength Index (RSI) 50.66 50.59
Support Level $0.58 $2.97
Resistance Level $0.88 $3.32
Average True Range (ATR) 0.08 0.26
MACD 0.13 0.06
Stochastic Oscillator 35.64 69.05

Price Performance

Historical Comparison
BHAT
LIXT

About BHAT Blue Hat Interactive Entertainment Technology

Blue Hat Interactive Entertainment Technology is focused on commodity trading, including chemicals, jewelry, and precious metals such as gold. It operates a gold and diamond trading and supply chain business. Its business model encompasses physical gold trading, diamond trading, gold derivatives trading, and the development of AI-enabled trading platforms. Its segments include Diamond trading, Commodity trading, Information service, Interactive toys - animation series, and Interactive toys - game series. It derives revenue from Diamond trading. The majority of its revenues are generated in PRC.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: